MIG 400 is a non-steroidal anti-inflammatory drug used to relieve pain of various origins.
Release form and composition
MIG 400 is produced in the form of film-coated tablets: oval, almost white or white, on the same side with a double-sided dividing line and embossed with “E” and “E” on both sides of the risks (in blisters of 10 pieces; 1 each or 2 blisters in a carton box).
The composition of 1 tablet includes:
- Active ingredient: ibuprofen - 400 mg;
- Auxiliary components: magnesium stearate - 5.6 mg; colloidal silicon dioxide - 13 mg; sodium carboxymethyl starch (type A) - 26 mg; corn starch - 215 mg.
The composition of the shell: macrogol 4000 - 0.56 mg, povidone K30 - 0.518 mg, titanium dioxide (E171) - 1.918 mg, hypromellose (viscosity 6 MPa · s) - 2.946 mg.
Indications for use
- Pain in muscles and joints;
- Menstrual pains;
- Fever with colds and flu.
- Aspirin Triad;
- Hemophilia and other bleeding disorders (including hypocoagulation), hemorrhagic diathesis;
- Deficiency of glucose-6-phosphate dehydrogenase;
- Diseases of the optic nerve;
- Bleeding of various etiologies;
- Erosive and ulcerative diseases of the gastrointestinal organs (including ulcerative colitis, Crohn's disease, peptic ulcer and duodenal ulcer in the acute phase);
- Age up to 12 years;
- Pregnancy and lactation;
- Hypersensitivity to the components of the drug, as well as to acetylsalicylic acid or other nonsteroidal anti-inflammatory drugs in history.
Conditions / diseases for which MIG 400 should be used with caution:
- Arterial hypertension;
- Hyperbilirubinemia, nephrotic syndrome, renal and / or liver failure;
- Blood diseases of unknown etiology (anemia and leukopenia);
- Colitis, enteritis, gastritis, gastric ulcer and duodenal ulcer (in history);
- Heart failure;
- Infectious diseases (the drug may mask their objective and subjective symptoms);
- Cirrhosis of the liver with portal hypertension;
- Elderly age.
Dosing and Administration
Tablets are taken orally.
Dosage regimen MIG 400 doctor sets individually, based on the evidence.
The initial dose of the drug for children over 12 years of age and adults, as a rule, is 200 mg 3-4 times a day. It can be increased by 2 times in cases where it is necessary to achieve a rapid therapeutic effect, in this case, the multiplicity of intake should not exceed 3 times a day. Once the therapeutic effect is achieved, the dose should be reduced to 600-800 mg per day.
It is not recommended to take MIG 400 for longer than 1 week or at a higher dosage. If it is necessary to use the drug for a longer period or in higher doses, consultation with a physician is required.
The dose of the drug must be reduced in case of kidney, liver or heart function.
During MIG 400 therapy, side effects may occur on the part of some body systems:
- Central and peripheral nervous system: hallucinations, confusion, depression, drowsiness, agitation, irritability and nervousness, anxiety, insomnia, dizziness, headache; rarely, aseptic meningitis (more often in patients with autoimmune diseases);
- Cardiovascular system: high blood pressure, tachycardia, heart failure;
- Urinary system: cystitis, polyuria, nephrotic syndrome (edema), allergic nephritis, acute renal failure;
- The digestive system: NPVS-gastropathy - constipation, flatulence, loss of appetite, heartburn, nausea, diarrhea, vomiting, abdominal pain; rarely, ulceration of the gastrointestinal mucosa, which in some cases is complicated by bleeding and perforation; possible - hepatitis, pancreatitis, aphthous stomatitis, ulceration of the mucous membrane of the gums, pain in the mouth, dryness or irritation of the oral mucosa;
- Respiratory system: bronchospasm, shortness of breath;
- Sense organs: conjunctival and eyelid edema (allergic genesis), scotoma, eye irritation and dryness, double vision or blurred vision, toxic damage to the optic nerve, tinnitus or tinnitus, hearing loss;
- Hematopoietic system: anemia (including aplastic, hemolytic), thrombocytopenic purpura and thrombocytopenia, leukopenia, agranulocytosis;
- Laboratory indicators: increased activity of hepatic transaminases, serum creatinine concentration, reduced creatinine, hematocrit or hemoglobin, decreased serum glucose concentration, increased bleeding time;
- Allergic reactions: eosinophilia, toxic epidermal necrolysis, allergic rhinitis, multiforme exudative erythema (including Stevens-Johnson syndrome), fever, dyspnea or bronchospasm, anaphylactic shock, anaphylactoid reactions, edema, dermatitis, skin anesthesia, anaphylactic shock, anaphylactoid reactions, edema, dermatitis, skin anemia, anaphylactic shock, anaphylactoid reaction, edema, dermatitis, anaphylactic shock, anaphylactoid reaction, edema, dermatitis, anesthesia
In the case of long-term use of the drug in high doses, the risk of developing visual impairment (damage to the optic nerve, scotoma, color vision disorder), bleeding (hemorrhoidal, uterine, gingival, gastrointestinal), and mucosal expressions of the gastrointestinal tract increases.
The drug should be canceled if there are signs of bleeding from the gastrointestinal tract, visual impairment (it is recommended to undergo an ophthalmologic examination).
In patients with allergic reactions or bronchial asthma in history or in the present, bronchospasm is possible.
Side effects can be reduced by using the minimum effective dose of MIG 400. In case of prolonged use of analgesics, the risk of analgesic nephropathy is possible.
Ibuprofen can increase the activity of liver enzymes.
During therapy, the picture of peripheral blood, the functional state of the liver and kidneys should be monitored.
In the event of symptoms of gastropathy, close monitoring is recommended, including a fecal occult blood test, a blood test with hematocrit, hemoglobin, and esophagogastroduodenoscopy.
Ethanol should not be consumed during therapy. To prevent the development of NSAIDs-gastropathy, ibuprofen is recommended to be used in combination with prostaglandin E (misoprostol).
If it is necessary to determine 17-ketosteroids, MIG 400 therapy should be discontinued 48 hours before the study.
Patients during treatment should refrain from conducting potentially hazardous activities that require quick psychomotor reactions and increased attention.
The effect of ibuprofen on drugs / substances with simultaneous use:
- Methotrexate: may increase its plasma concentration;
- Thiazide diuretics, furosemide, antihypertensive drugs: may reduce their effectiveness;
- Oral anticoagulants: may enhance their effect (simultaneous use is not recommended);
- Acetylsalicylic acid (ASA): reduces its antiplatelet effect;
- Lithium, phenytoin, digoxin: can increase their plasma concentrations (isolated cases have been noted);
- Oral hypoglycemic agents, insulin: increases their hypoglycemic effect (may require dose adjustment).
Like other nonsteroidal anti-inflammatory drugs (NSAIDs), ibuprofen should be used with caution in combination with ASA, glucocorticosteroids and other NSAIDs, since such combinations increase the risk of adverse effects of MIG 400 on the gastrointestinal tract.
The use of ibuprofen in combination with zidovudine may increase the risk of hematoma and hemarthrosis in HIV-infected patients with hemophilia; with tacrolimus - increase the risk of nephrotoxic action (due to impaired prostaglandin synthesis in the kidneys).
Terms and conditions of storage
To store in protected from light and the unavailable to children place at a temperature up to 30 ° C.
Shelf life - 3 years.